Eporgen commenced operations in 2005 and is based in the “Silvano Fumero” Bioindustry Park, close to Ivrea in the Piedmont region of Italy.

Since its creation, Eporgen has experienced a steady growth and today has doubled its original portfolio to a total of 11 start-up companies with 19 patents, its investor base to a total of 70 investors and the amount of money raised to a total of €7.8m in four subsequent financing rounds. Eporgen has also successfully participated in a number of public Italian and European financing initiatives and has received to date over €1m in grants.

With about 30 staff in total, Eporgen and its start-up companies operate an efficient business model that combines aspects of a venture capital and a virtual pharma company and relies on a network of scientific advisors, contract research organisations and academic institutions.

About half the start-up companies in Eporgen’s portfolio have reached or are about to reach proof-of-concept stage and are/will be seeking partnerships for further development of their technology.